Leo Frans Groothuis
CIK: 0001978507
Associated companies
Transaction History
| VTRS | ▲ Buy | Option Exercise | 1,175 | $0 | 3/6/2026 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 62 | $878 | 3/6/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 23,660 | $0 | 3/6/2026 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 1,243 | $18K | 3/6/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 18,204 | $0 | 3/4/2025 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 1,166 | $11K | 3/4/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 773 | $0 | 3/4/2025 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 50 | $468 | 3/4/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 21,954 | $0 | 3/3/2024 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 330 | $4K | 3/3/2024 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 530 | $0 | 3/3/2024 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 8 | $101 | 3/3/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal
Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.
Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal. Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.